Avutometinib

艾沃美替尼

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameAvutometinib
Drug Alias NameAVMAPKICH-5126766VS-6766RG-7304R-7304 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsRAF serine/threonine protein kinase inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1RAF serine/threonine protein kinase
Therapy Area/IndicationsUveal melanomaBrain metastasesSkin Melanoma +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesChugai Pharmaceutical Co LtdThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdChugai Pharma USA, IncMirati Therapeutics Inc +[7] 
Inactive CompaniesF. Hoffmann-La Roche LtdThe University Of ChicagoThomas Jefferson University
Active IndicationsBrain metastasesSkin MelanomaSolid tumours +[21] 
Inactive IndicationsUveal melanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG